gefitinib (Iressa)
Jump to navigation
Jump to search
Introduction
Tradname: Iressa (FDA approved 2003)
Indications
- refractory or metastatic non-small cell lung cancer[3]*
- NOT recemmended (NICE) [NGC]
- head & neck cancer
- CML[2]
* NSCLC with EGFR mutation (exon 19 deletions or exon 21 L858R substitution gene mutations)[3]
* ~10% of tumors shrink in size
* NOT recemmended (NICE) [NGC]
Dosage
Adverse effects
- drug adverse effects of tyrosine kinase inhibitor(s)
- drug adverse effects of EGF receptor inhibitors
Laboratory
- therascreen EGFR RGQ PCR approved as a companion molecular diagnostic test[3]
Mechanism of action
More general terms
References
- ↑ Prescriber's Letter 10(6):35 2003
- ↑ 2.0 2.1 2.2 Medical Knowledge Self Assessment Program (MKSAP) 16, American College of Physicians, Philadelphia 2012
- ↑ 3.0 3.1 3.2 3.3 FDA News Release. July 13, 2015 FDA approves targeted therapy for first-line treatment of patients with a type of metastatic lung cancer http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm454678.htm